EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Predictors of persistent disease in biologic treated type 2 diffuse/eosinophilic chronic rhinosinusitis undergoing surgery

Lu Hui Png iD, Larry Kalish, Raewyn G Campbell, Kachorn Seresirikachorn iD, Tobias Albrecht, Nelufer Raji, Christine Choy, Janet Rimmer, Peter Earls, Raymond Sacks, Richard J Harvey iD

International Forum of Allergy & Rhinology · 2024

DOI: 10.1002/alr.23282 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Forum of Allergy & Rhinology, 2024. Verfasst von Lu Hui Png und 10 weiteren Autor:innen. Beteiligte Einrichtung: Rhinology and Skull Base Research Group, St Vincent's Centre for Applied Medical Research, University of New South Wales, Sydney, Australia. Hauptthemen laut MEDLINE: Biological Products, Eosinophils, Nasal Polyps, Rhinosinusitis. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Biologic therapy targeting type 2 chronic rhinosinusitis with nasal polyps (CRSwNP) has greatly improved disease control but nonresponders exist in a proportion of patients in phase 3 trials and clinical practice. This study explores the serum and histologic changes in biologic treated CRSwNP that predict disease control.

Methods

A cross‐sectional study was performed of patients with CRSwNP on biologics for their asthma, who underwent endoscopic sinus surgery while on biologic therapy. At the 6‐month postoperative assessment, patients with poorly controlled CRSwNP while on biologic therapy were compared to patients who were controlled. Blood and mucosal samples taken at the time of surgery 6 months prior were assessed to predict disease control.

Results

A total of 37 patients were included (age 47.8 ± 12.4 years, 43.2% female). Those with poorly controlled disease had reduced tissue eosinophils (% >100 cells/high‐powered field: 8.3% vs. 50.0%, p < 0.001) and increased serum neutrophils (5.2 ± 2.7 vs. 3.7 ± 1.1 × 10 9 cells/L, p = 0.02). Logistic regression analysis demonstrated that reduced tissue eosinophil was predictive for poorly controlled disease (OR = 0.21, 95% CI [0.05, 0.83], p = 0.03). Receiver‐operating characteristic analysis showed that need for rescue systemic corticosteroid was predicted at a serum neutrophil cut‐off level of 5.75 × 10 9 cells/L (sensitivity = 80.0%, specificity = 96.9%, AUC = 0.938, p = 0.002).

Conclusion

Low tissue eosinophils and increased serum neutrophils while on biologics predict for poor response in the biological treatment of with CRSwNP. A serum neutrophil level of ≥5.75 × 10 9 cells/L predicts for poor response to current biologic therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biological ProductsEosinophilsNasal PolypsRhinosinusitisAdultFemaleHumansMaleMiddle AgedAsthmaChronic DiseaseCross-Sectional StudiesEosinophiliaNeutrophils

Stichwörter der Autor:innen

biologicsbiomarkersnasal polypsresident eosinophilssinusitistherapeutic responsetype 2 inflammation

Substanzen

Biological Products

Autor:innen und Institutionen

  • Rhinology and Skull Base Research Group, St Vincent's Centre for Applied Medical Research, University of New South Wales, Sydney, Australia.
  • Department of Otorhinolaryngology - Head and Neck Surgery, Singapore General Hospital, Singapore, Singapore.
  • Faculty of Medicine and Health Sciences, Macquarie University, Sydney, Australia.
  • Department of Otolaryngology, Head and Neck Surgery, Concord General Hospital, University of Sydney, Sydney, Australia.
  • Faculty of Medicine, University of Sydney, Sydney, Australia.
  • Department of Otolaryngology, Head and Neck Surgery, Royal Prince Alfred Hospital, Sydney, Australia.

ORCID-Profile: Lu Hui Png, Kachorn Seresirikachorn, Richard J Harvey

Zitieren

APA

Png, L. H., Kalish, L., Campbell, R. G., Seresirikachorn, K., Albrecht, T., Raji, N., Choy, C., Rimmer, J., Earls, P., Sacks, R., & Harvey, R. J. (2024). Predictors of persistent disease in biologic treated type 2 diffuse/eosinophilic chronic rhinosinusitis undergoing surgery. International Forum of Allergy & Rhinology. https://doi.org/10.1002/alr.23282

Vancouver

Png LH, Kalish L, Campbell RG, Seresirikachorn K, Albrecht T, Raji N, et al. Predictors of persistent disease in biologic treated type 2 diffuse/eosinophilic chronic rhinosinusitis undergoing surgery. International Forum of Allergy & Rhinology. 2024. doi:10.1002/alr.23282

BibTeX
@article{Png2024,
  author = {Png, Lu Hui and Kalish, Larry and Campbell, Raewyn G and Seresirikachorn, Kachorn and Albrecht, Tobias and Raji, Nelufer and Choy, Christine and Rimmer, Janet and Earls, Peter and Sacks, Raymond and Harvey, Richard J},
  title = {Predictors of persistent disease in biologic treated type 2 diffuse/eosinophilic chronic rhinosinusitis undergoing surgery},
  journal = {International Forum of Allergy & Rhinology},
  year = {2024},
  doi = {10.1002/alr.23282}
}
Kostenlos starten →